Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 755 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: End Stage Kidney Disease Clear all
Recruiting Phase 3 Interventional

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

NCT05931276
View directory record Official record
Conditions
End-Stage Kidney Disease, End-Stage Renal Disease
Interventions
Metoprolol Succinate, Carvedilol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Long Beach, California • Gainesville, Florida • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

NCT00237718
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Alpha, gamma, beta, and delta (mixed) tocopherols, Alpha lipoic acid, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease

NCT01530945
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Testing to Understand and Address Renal Disease Disparities

NCT02234063
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease, Genomics
Interventions
Immediate Genetic Testing
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
2,052 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

NCT00374803
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Mycophenolic Acid (Myfortic)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients

NCT02165761
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GORE® Hybrid Vascular Graft, Non-heparin bonded synthetic graft
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Hackensack, New Jersey • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

NCT04678505
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3402
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Dialysis Patients

NCT01450670
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 23, 2026, 8:15 PM EDT
Not listed Not applicable Interventional

Alio WEAR Study: Long-term Wear of the Alio Platform

NCT06056739
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Alio platform
Device
Lead sponsor
Alio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Huntley, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

NCT00844662
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Fermagate, Sevelamer hydrochloride
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Hot Springs, Arkansas • Bakersfield, California • Lynwood, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 23, 2026, 8:15 PM EDT
No Longer Available No phase listed Expanded access

Islet Transplant for Type 1 or Surgical Diabetes

NCT01606475
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions
Allogeneic islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT03617536
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Premarket Clinical Safety Assessment of the ELISIO™-HX

NCT07058909
View directory record Official record
Conditions
Renal Failure, Acute Renal Failure, Chronic Renal Failure, Chronic Kidney Diseases, End Stage Renal Disease
Interventions
ELISIO™-HX Dialyzer
Device
Lead sponsor
Nipro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Sit Less, Interact, Move More (SLIMM) Regimen on Patients With Chronic Kidney Disease (CKD)

NCT02924298
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease
Interventions
SLIMM
Behavioral
Lead sponsor
Srinvasan Beddhu
Other
Eligibility
18 Years to 95 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 23, 2026, 8:15 PM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

NCT01459250
View directory record Official record
Conditions
Renal Impairment
Interventions
AGO178C
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

NCT00742716
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTA018 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

NCT03873038
View directory record Official record
Conditions
Renal Dialysis, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

NCT06613568
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Moda-flx Hemodialysis System™
Device
Lead sponsor
Diality Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
San Dimas, California • New Hyde Park, New York • Knoxville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention

NCT01052220
View directory record Official record
Conditions
Hypertension, Hemodialysis
Interventions
BP education and BP self-regulation, Supportive Educative Nursing Intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation

NCT04032613
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Vascular Access Navigation and Education Quality Improvement Program
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis

NCT00939952
View directory record Official record
Conditions
Continuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease
Interventions
ertapenem
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Clifton Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients

NCT00179140
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplementation, exercise
Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 23, 2026, 8:15 PM EDT